Head-to-head · Cost-Efficiency Index
Gatlan vs Joey Med
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Gatlan
Cost-first shoppers who want named clinical leadership (Dr. Robert Lufkin) over transparent per-dose pricing, which the site does not publish.
Visit GatlanJoey Med
Shoppers who want to pick a molecule-agnostic 'Core / Plus Core' tier and pay per 4, 8, or 12 weeks rather than a recurring monthly subscription.
Visit Joey MedThe verdict
Gatlan and Joey Med tie on the Cost-Efficiency Index at 54/100, so neither wins outright on the numbers. For most shoppers we'd start with Gatlan (ranked #354, a hair above #356) — Cost-first shoppers who want named clinical leadership (Dr. Robert Lufkin) over transparent per-dose pricing, which the site does not publish. But Joey Med is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Gatlan.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Gatlan | Joey Med |
|---|---|---|
| Cost-Efficiency Index | 54/100 | 54/100 |
| Semaglutide / mo | Not disclosed | $199/mo (promotional rate, compounded) |
| Tirzepatide / mo | $199/mo (starting dose, compounded) | $275/mo (promotional rate, compounded) |
| Semaglutide / yr (modeled) | — | $2,388 |
| Tirzepatide / yr (modeled) | $2,388 | $3,300 |
| Coverage | 44 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #354 | #356 |
Gatlan
54/100Where the value is
- Named Chief Medical Advisor with verifiable academic credentials — Dr. Robert Lufkin, UCLA/USC
- 44 states are listed by name in the footer, so coverage can be checked without starting sign-up
- A real 'From $199/mo' price point is published without requiring signup, even though it isn't broken out by drug or dose
The tradeoffs
- The '$199/mo' figure is a bare 'starting at' number — no dose, no named drug, and no indication of what happens to price at higher doses
- No LegitScript badge found on any page reached
Joey Med
54/100Where the value is
- The site's own embedded pricing data is fully itemized by tier (4/8/12 weeks) for all three products
- Molecule names are disclosed on the category page even though individual product pages use branded tier names
- Legal entity is disclosed via the site's own structured data: MD Telehealth Platform LLC DBA Joey Med
The tradeoffs
- The current roster's prices were stale: $279 was the crossed-out list price for semaglutide (actual: $199), and $399 belonged to the High Dose tirzepatide tier, not the standard $275 entry tier
- Drug names are buried under branded tier names on the product pages themselves
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.